Intrapleural Hemocoagulase Outcomes After VATS for Stage IA Lung Cancer

Yingding Ruan's study analyzes 442 stage IA non-small cell lung cancer patients undergoing video-assisted thoracoscopic surgery (VATS), comparing outcomes between those receiving intrapleural hemocoagulase Bothrops atrox (HBA) and a control group. The dataset, last updated in April 2026, includes postoperative coagulation profiles, complication rates, and hospital length of stay. The analysis uses inverse probability of treatment weighting to balance baseline characteristics.

Use Cases

• Modeling the association between hemocoagulase use and postoperative coagulation parameters like prothrombin time and fibrinogen levels.
• Predicting postoperative complication risk based on treatment group and patient characteristics.
• Analyzing factors influencing length of hospital stay after video-assisted thoracoscopic surgery.

Strengths

• Study includes 442 patient records, providing a substantial sample for analysis.
• Results are based on statistical adjustment (inverse probability of treatment weighting) to balance groups.
• Specific numerical outcomes are reported, such as a 6.5% vs. 12.0% complication rate between groups.

Limitations

• Row count and column-level documentation are unknown, limiting suitability assessment.
• Data is derived from a retrospective study, which may introduce inherent biases.
• The dataset is very small at 25.9 KB, indicating limited scope or summary-level data.

Provenance

Source

Yingding Ruan via figshare

Collection Method

Retrospective analysis of patient records.

Time Range

null

Freshness

Last updated 2026-04-10 05:29:36; freshness should be verified.

Geography

null